Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer

Shuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, Hozumi Kumagai Shimokawa, Gen Hirano, Akitaka Makiyama, Yoshihiro Shibata, Shingo Tamura, Taito Esaki, Kenji Mitsugi, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.

Original languageEnglish
Pages (from-to)1959-1966
Number of pages8
JournalAnticancer research
Volume36
Issue number4
Publication statusPublished - Apr 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this